Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Nov 7, 2022--
The "Global Celiac Disease Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The global celiac disease market is anticipated to grow significantly at a CAGR of 8.5% during the forecast period.
Celiac disease is a digestive disorder in which the body has trouble absorbing nutrients such as lipids, calcium, iron, and folate. It is an autoimmune illness induced by eating gluten, which damages the small intestine's inner lining. Several diseases and conditions, including neurological abnormalities, infertility, reduced bone density, and some cancers, can be caused by the disease.
People with type 1 diabetes, down syndrome, autoimmune thyroid disease, microscopic colitis, Addison's disease, and rheumatoid arthritis are at risk for this hereditary condition. Besides, the market for celiac disease therapy is predicted to rise significantly in the forecast period, owing to the development of several anti-inflammatory medications and therapeutic vaccinations that will replace or enhance a gluten-free diet.
The organization of various awareness programs and initiatives taken by the government in various nations for the treatment of celiac disease is a major factor that is driving the growth of the global celiac disease market. With such actions, the government may significantly stimulate market growth.
Furthermore, numerous funds are available for R&D operations, which is propelling market expansion. For instance, in 2015, in Italy, children and adults with certain symptoms are tested for celiac disease. Diagnosed celiacs are given vouchers worth up to $168 per month to spend on specially made gluten-free meals. Furthermore, restaurants are educated on how to deal with celiac disease by the Italian Celiac Association and the government. Gluten-free meals are even available at hospitals, schools, and other public eating facilities.
Impact of COVID-19 Pandemic on Global Celiac Disease Market
The global celiac disease market is hit by the COVID-19 pandemic in December 2019. The excruciating need to screen and test large numbers of patients for potential SARS-Cov-2 infection is the most common problem for governments in all COVID-19-affected countries. As the new virus's rapid spread continues to affect communities around the globe, celiac disease susceptibility and risk levels have become a source of concern for the celiac community.
The limits imposed to combat COVID-19 may have an impact on celiac disease treatment and gluten-free eating, which is now the sole treatment option for celiac disease. Apart from it, major players were focusing on the clinical trials for the celiac disease therapies, due to the pandemic trials was suspended and impacted negatively on the market growth. The market will witness "V" shape recovery in near future owing to the restart of activities in major economies.
Market Players Outlook
The key players of the global celiac disease market include Abbott Laboratories, Eli Lilly & Co, Novartis AG, Johnson & Johnson, BioLineRx Ltd., Amgen Inc., Siemens AG, and Bayer AG among others.
The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.
The Report Covers
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Celiac Disease Market by Treatment Type
5.2. Global Celiac Disease Market by Diagnostic Type
5.3. Global Celiac Disease Market by End-User
6. Regional Analysis
7. Company Profiles
7.1. Abbott Laboratories
7.2. AbbVie Inc.
7.3. ADMA Biologics, Inc.
7.4. Amgen Inc.
7.5. Bayer AG
7.6. Bio Rad Laboratories, Inc.
7.7. BioLineRX Ltd.
7.8. Boston Scientific Corp.
7.9. Bristol-Myers Squibb Co.
7.10. Calypso Biotech SA
7.11. ChemoCentryx, Inc.
7.12. Eli Lilly And Co.
7.13. GlaxoSmithKline plc
7.14. ImmunogenX, Inc.
7.15. Janssen Pharmaceuticals, Inc.
7.16. Johnson & Johnson Services Inc.,
7.17. Merck & Co., Inc.,
7.18. Sanofi S.A
7.19. Thermo Fisher Scientific Inc.
7.20. ZEDIRA GmbH
For more information about this report visit https://www.researchandmarkets.com/r/azvqcg
View source version on businesswire.com:https://www.businesswire.com/news/home/20221107005915/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: RESEARCH OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL CONSUMER TECHNOLOGY FITNESS & NUTRITION SCIENCE OTHER CONSUMER BIOTECHNOLOGY HEALTH FOOD TECH OTHER SCIENCE
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/07/2022 12:22 PM/DISC: 11/07/2022 12:22 PM
http://www.businesswire.com/news/home/20221107005915/en